Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma (GEMOXIA-02)
Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma: a Multicentric Single-arm Phase II Study
Sponsor: Federation Francophone de Cancerologie Digestive
This PHASE2 trial investigates Cholangiocarcinoma Non-resectable and Non-metastatic and is currently actively recruiting participants. Federation Francophone de Cancerologie Digestive leads this study, which shows 11 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
-
Feb 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 6 earlier versions
-
Jun 2023 — Feb 2024 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Feb 2023 — Jun 2023 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Feb 2023 [monthly]
Recruiting PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Feb 2020 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Federation Francophone de Cancerologie Digestive
- University Hospital, Montpellier
For direct contact, visit the study record on ClinicalTrials.gov .